According to NIDA Director Dr. Nora Volkow, “NIH and NIDA are committed to an ‘all scientific hands on deck’ effort to end the opioid crisis in America by halving the time it takes to develop new medications to treat pain and addiction and reverse overdoses.”

The goals of the new initiative range from innovative and ambitious new treatment approaches that will take some time to develop, such as vaccines or transcranial magnetic stimulation for pain and addiction, to goals that are relatively achievable in the short term, such as improved formulations of existing medications.

New formulations of injectable buprenorphine from Indivior and Braeburn have been granted priority review. The FDA is slated to make decisions by November 30, 2017 and January 10, 2018, respectively.

Read More

Indivior Details

Braeburn Details